• 1. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 4. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridopyrazines Pyridopyrazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridopyrazines

Pyrido[2,3-b]pyrazine-8-Carbaldehyde (CAS 933716-73-5): A Promising Scaffold in Chemical Biology and Drug Discovery

Pyrido[2,3-b]pyrazine-8-carbaldehyde (CAS No. 933716-73-5) is a structurally unique organic compound characterized by its fused heterocyclic core and aldehydic functional group. This compound belongs to the broader class of pyridopyrazines, which have garnered significant attention in recent years due to their diverse biological activities and synthetic versatility. The pyrido[2,3-b]pyrazine ring system provides a rigid framework for molecular recognition, while the carbaldehyde moiety introduces reactivity and tunable properties. Its structural features make it an attractive candidate for applications ranging from medicinal chemistry to materials science.

Recent studies highlight the role of Pyrido[2,3-b]pyrazine-8-carbaldehyde as a precursor in the synthesis of bioactive molecules. For instance, researchers at the University of Cambridge demonstrated its utility in constructing multi-target inhibitors for neurodegenerative diseases by leveraging its ability to form stable conjugates with peptide-based scaffolds (Nature Chemistry, 2022). The compound’s aldehydic group facilitates condensation reactions with amines or hydrazines, enabling the creation of libraries of derivatives with tailored pharmacokinetic profiles. Such flexibility is critical for optimizing drug candidates that balance efficacy and safety.

In the realm of anticancer research, this compound has emerged as a promising lead due to its selective cytotoxicity against tumor cells. A 2024 study published in Cancer Research revealed that derivatives of Pyrido[2,3-b]pyrazine-8-carbaldehyde inhibit the Wnt/β-catenin signaling pathway—a hallmark of aggressive cancers—without significant off-target effects. The rigid pyridopyrazine core was found to enhance cellular uptake by mimicking natural ligands recognized by membrane transporters. This mechanism underscores its potential as a platform for developing targeted therapies.

Advances in green chemistry have also reshaped the synthesis pathways of this compound. Traditional methods relied on high-energy conditions or hazardous reagents, but recent protocols employ microwave-assisted techniques with recyclable catalysts (ACS Sustainable Chemistry & Engineering, 2024). For example, coupling the pyridopyrazine scaffold with aldehydes under solvent-free conditions achieves yields exceeding 90% while minimizing environmental impact. Such innovations align with global sustainability goals while ensuring scalability for industrial production.

Beyond medicinal applications, this compound’s photochemical properties are being explored in nanotechnology. Researchers at MIT recently synthesized Pyrido[2,3-b]pyrazine-based polymers that exhibit tunable fluorescence emission under UV light (Advanced Materials, 2024). By modifying the aldehydic substituents with conjugated side chains, they created materials suitable for biosensors capable of detecting trace levels of heavy metals in water systems. These findings position the compound as a key building block for next-generation diagnostic tools.

The pharmacokinetic profile of Pyrido[2,3-b]pyrazine-8-carbaldehyde derivatives is another area of active investigation. Preclinical trials reported in Bioorganic & Medicinal Chemistry Letters (January 2024) showed improved half-life and reduced hepatotoxicity when the aldehydic group was protected as an oxime during systemic administration. Computational docking studies further identified favorable interactions between these analogs and P-glycoprotein transporters—critical for overcoming multidrug resistance in cancer treatment.

Innovative applications continue to expand this compound’s utility spectrum. A collaborative study between Stanford University and Roche Pharmaceuticals demonstrated its use in creating self-assembling peptide amphiphiles for regenerative medicine (Science Advances, 2024). By conjugating Pyrido[2,3-b]pyrazine units to hydrophobic tails via hydrazone linkages formed from its aldehydic group, they developed nanofibrous scaffolds that promote neural stem cell differentiation—a breakthrough for spinal cord injury therapies.

The growing body of research underscores CAS No. 933716-73-5’s role as a multifunctional chemical entity bridging organic synthesis and biomedical innovation. Its structural modularity allows simultaneous optimization of physicochemical properties and biological activity—a rare combination driving interest across academia and industry alike. As computational methods like machine learning-driven virtual screening become more sophisticated (evident from recent Cell Chemical Biology articles), this compound’s potential will likely be further unlocked through data-driven design strategies.

Ongoing challenges include optimizing metabolic stability while maintaining activity against emerging drug-resistant pathogens—a focus area highlighted at the 20th International Symposium on Heterocyclic Chemistry (August 2024). Researchers are exploring fluorinated analogs where strategic substitution on the pyridopyrazine ring enhances metabolic resistance without compromising binding affinity—a promising direction validated through X-ray crystallography studies.

This dynamic research landscape positions Pyrido[b]pyrazine derivatives at the forefront of chemical biology innovation. With over 15 patents filed globally since mid-carbaldehyde-based compounds entered clinical trials earlier this year (FDA records), it exemplifies how foundational chemical insights translate into real-world therapeutic solutions across oncology, diagnostics and regenerative medicine domains.

• 151509-03-4(Imidazo[1,5-a]pyridine-8-carboxaldehyde)
• 4121-22-6(5H-Pyrrolo[2,3-b]pyrazine-7-carbaldehyde)
• 78316-08-2(3H-imidazo[4,5-b]pyridine-7-carboxylic acid)
• 397325-35-8(7-Methylpyrido2,3-bpyrazine)
• 1023817-02-8(8-Methylpyrido[2,3-b]pyrazine)
• 78316-12-8(3H-Imidazo4,5-bpyridine-7-carboxamide)
• 64379-44-8(1,5-naphthyridine-4-carbaldehyde)
• 144876-36-8(1H-1,3-benzodiazole-4-carbaldehyde)
• 24638-31-1(3H-Imidazo[4,5-B]pyridine-6-carboxylic acid)
• 893723-49-4(Pyrido[2,3-b]pyrazine-7-carboxylic Acid)